Skip to main content
CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
5.00
+0.32 (6.84%)
Mar 9, 2026, 2:33 PM EDT - Market open

CytomX Therapeutics Revenue

CytomX Therapeutics had revenue of $5.96M in the quarter ending September 30, 2025, a decrease of -82.16%. This brings the company's revenue in the last twelve months to $113.63M, down -10.26% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.

Revenue (ttm)
$113.63M
Revenue Growth
-10.26%
P/S Ratio
6.98
Revenue / Employee
$939,099
Employees
121
Market Cap
847.18M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024138.10M36.89M36.45%
Dec 31, 2023101.21M48.05M90.38%
Dec 31, 202253.16M15.85M42.48%
Dec 31, 202137.31M-31.12M-45.47%
Dec 31, 202068.43M41.53M154.36%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
MannKind 348.97M
Xencor 125.58M
Kura Oncology 67.48M
Evommune 13.00M
KalVista Pharmaceuticals 1.43M
Revenue Rankings

CTMX News

More News